RNA-based therapeutic developer DTx Pharma announced today that it completed a $100 million Series B financing round. RA Capital Management led the financing round with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital. Additionally, existing investors Friedman Bioventure Fund, Eli Lilly, Viva BioInnovator […]